Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04824950 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)

Study acronym: CAMIL
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The purpose of this study is to compare the predictive value in terms of specificity of circulating tumor DNA (ctDNA) and positron emission computed tomography (PET-CT) after 2 cycles of chemotherapy (C2), on the probability of obtaining a metabolic complete response after 4 cycles of induction chemotherapy (C4) in patients with primary mediastinal large B cell lymphoma (PMBL) receiving standard R-CHOP14 or R-ACVBP.
Trial Details
NCT Number NCT04824950
Lead Sponsor Centre Henri Becquerel
Conditions
(from sponsor)		 Primary Mediastinal Large B-cell Lymphoma
Enrollment 87 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov